Optical Coherence tomography detection of neurodegeneration in multiple sclerosis

CNS and Neurological Disorders - Drug Targets

Volumn 11, Issue 5, 2012, Pages 518-527

  Lidster, Katie ^a   Baker, David ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Multiple sclerosis; Neuroprotection; Optic neuritis; Optical coherence tomography; Retinal nerve fibre layer

Indexed keywords

BETA1A INTERFERON; BIIB 017; FLUPIRTINE; GLATIRAMER; INTERFERON BETA SERINE; MINOCYCLINE; NATALIZUMAB; PHENYTOIN; UNCLASSIFIED DRUG;

CENTRAL NERVOUS SYSTEM; DEMYELINATION; HUMAN; INFLAMMATION; MEDICAL RESEARCH; MULTIPLE SCLEROSIS; NERVE DEGENERATION; NERVE FIBER; NEURITIS; NEUROPROTECTION; OPTIC NEURITIS; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; RETINA; REVIEW; VISUAL SYSTEM;

EID: 84863977769     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/187152712801661185     Document Type: Review

References (98)

1. Bitsch, A.; Schuchardt, J.; Bunkowski, S.; Kuhlmann, T.; Bruck, W. Acute axonal injury in multiple sclerosis: Correlation with demyelination and inflammation. Brain, 2000, 123(6), 1174-1183.
2. Trapp, B.D.; Peterson, J.; Ransohoff, R.M.; Rudick, R.; Mork, S.; Bo, L. Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med., 1998, 338(5), 278-285.
3. Bjartmar, C.; Wujek, J.R.; Trapp, B.D. Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease. J. Neurol. Sci., 2003, 206, 165-171.
4. Confavreux, C.; Vukusic, S. Non-specific immunosuppressants in the treatment of multiple sclerosis. Clin. Neurol. Neurosurg., 2004, 106(3), 263-269.
5. Keeler, C.R. The ophthalmoscope in the lifetime of Hermann von Helmholtz. Arch. Ophthalmol., 2002, 120(2), 194-201.
6. Huang, D.; Swanson, E.; Lin, C.; Schuman, J.; Stinson, W.; Chang, W.; Hee, M.; Flotte, T.; Gregory, K.; Puliafito, C.; Fujimoto, J. Optical coherence tomography. Science, 1991, 254(5035), 1178-1181.
7. Hee, M.R.; Izatt, J.A.; Swanson, E.A.; Huang, D.; Schuman, J.S.; Lin, C.P.; Puliafito, C.A.; Fujimoto, J.G. Optical coherence tomography of the human retina. Arch. Ophthalmol., 1995, 113(3), 325-332.
8. Swanson, E.A.; Izatt, J.A.; Hee, M.R.; Huang, D.; Lin, C.P.; Schuman, J.S.; Puliafito, C.A.; Fujimoto, J.G. In vivo retinal imaging by optical coherence tomography. Opt. Lett., 1993, 18(21), 1864-1866.
9. Fercher, A.F. Optical coherence tomography-development, principles, applications. Zeitschrift für Medizinische Physik, 2010, 20(4), 251-276.
10. Chan, A.; Duker, J.S.; Ko, T.H.; Fujimoto, J.G.; Schuman, J.S. Normal macular thickness measurements in healthy eyes using stratus optical coherence tomography. Arch. Ophthalmol., 2006, 124(2), 193-198.
11. Drexler, W.; Sattmann, H.; Hermann, B.; Ko, T.H.; Stur, M.; Unterhuber, A.; Scholda, C.; Findl, O.; Wirtitsch, M.; Fujimoto, J.G.; Fercher, A.F. Enhanced visualization of macular pathology with the use of ultrahigh-resolution optical coherence tomography. Arch. Ophthalmol., 2003, 121(5), 695-706.
12. Alam, S.; Zawadzki, R.J.; Choi, S.; Gerth, C.; Park, S. S.; Morse, L.; Werner, J.S. Clinical application of rapid serial fourier-domain optical coherence tomography for macular imaging. Ophthalmology, 2006, 113(8), 1425-1431.
13. Potsaid, B.; Gorczynska, I.; Srinivasan, V.J.; Chen, Y.; Jiang, J.; Cable, A.; Fujimoto, J.G. Ultrahigh speed spectral/Fourier domain OCT ophthalmic imaging at 70,000 to 312,500 axial scans per second. Opt. Express, 2008, 16(19), 15149-15169.
14. Hangai, M.; Ojima, Y.; Gotoh, N.; Inoue, R.; Yasuno, Y.; Makita, S.; Yamanari, M.; Yatagai, T.; Kita, M.; Yoshimura, N. Threedimensional imaging of macular holes with high-speed optical coherence tomography. Ophthalmology, 2007, 114(4), 763-773.
15. Wojtkowski, M.; Srinivasan, V.; Fujimoto, J.G.; Ko, T.; Schuman, J.S.; Kowalczyk, A.; Duker, J.S. Three-dimensional retinal imaging with high-speed ultrahigh-resolution optical coherence tomography. Ophthalmology, 2005, 112(10), 1734-1746.
16. Schuman, J.S.; Hee, M.R.; Arya, A.V.; Pedut-Kloizman, T.; Puliafito, C.A.; Fujimoto, J.G.; Swanson, E.A. Optical coherence tomography: a new tool for glaucoma diagnosis. Curr. Opin. Ophthalmol., 1995, 6(2), 89-95.
17. Puliafito, C.A.; Hee, M.R.; Lin, C.P.; Reichel, E.; Schuman, J.S.; Duker, J.S.; Izatt, J.A.; Swanson, E.A.; Fujimoto, J.G. Imaging of macular diseases with optical coherence tomography. Ophthalmology, 1995, 102(2), 217-229.
18. Rao, B.; Zhang, J.; Taban, M.; McDonnell, P.; Chen, Z. Imaging and investigating the effects of incision angle of clear corneal cataract surgery with optical coherence tomography. Opt. Express, 2003, 11(24), 3254-3261.
19. Akasaka, T.; Kubo, T.; Mizukoshi, M.; Tanaka, A.; Kitabata, H.; Tanimoto, T.; Imanishi, T. Pathophysiology of acute coronary syndrome assessed by optical coherence tomography. J. Cardiol., 2010, 56(1), 8-14.
20. Feldchtein, F.; Gelikonov, V.; Iksanov, R.; Gelikonov, G.; Kuranov, R.; Sergeev, A.; Gladkova, N.; Ourutina, M.; Reitze, D.; Warren, J. In vivo OCT imaging of hard and soft tissue of the oral cavity. Opt. Express, 1998, 3(6), 239-250.
21. Boppart, S.A.; Tearney, G.J.; Bouma, B.E.; Southern, J.F.; Brezinski, M.E.; Fujimoto, J.G. Noninvasive assessment of the developing Xenopus cardiovascular system using optical coherence tomography. Proc. Natl. Acad. Sci. USA, 1997, 94(9), 4256-4261.
22. Petzold, A.; de Boer, J.F.; Schippling, S.; Vermersch, P.; Kardon, R.; Green, A.; Calabresi, P.A.; Polman, C. Optical coherence tomography in multiple sclerosis: a systematic review and metaanalysis. Lancet Neurol., 2010, 9(9), 921-932.
23. Paquet, C.; Boissonnot, M.; Roger, F.; Dighiero, P.; Gil, R.; Hugon, J. Abnormal retinal thickness in patients with mild cognitive impairment and Alzheimer's disease. Neurosci. Lett., 2007, 420(2), 97-99.
24. Lu, Y.; Li, Z.; Zhang, X.; Ming, B.; Jia, J.; Wang, R.; Ma, D. Retinal nerve fiber layer structure abnormalities in early Alzheimer's disease: evidence in optical coherence tomography. Neurosci Lett., 2010, 480(1), 69-72.
25. Hajee, M.E.; March, W.F.; Lazzaro, D.R.; Wolintz, A.H.; Shrier, E.M.; Glazman, S.; Bodis-Wollner, I.G. Inner retinal layer thinning in Parkinson disease. Arch. Ophthalmol., 2009, 127(6), 737-741.
26. Valenti, D.A. Alzheimer's disease and glaucoma: imaging the biomarkers of neurodegenerative disease. Int. J. Alzheimers Dis., 2011, 2010, 793931.
27. Selhorst, J.B.; Chen, Y. The Optic Nerve. Semin. Neurol., 2009, 29(01), 29-35.
28. Hickman, S.J.; Dalton, C.M.; Miller, D.H.; Plant, G.T. Management of acute optic neuritis. Lancet, 2002, 360(9349), 1953-1962.
29. Cleary, P.A.; Beck, R.W.; Bourque, L.B.; Backlund, J.C.; Miskala, P.H. Visual symptoms after optic neuritis. Results from the Optic Neuritis Treatment Trial. J. Neuroophthalmol., 1997, 17(1), 18-23; quiz 4-8.
30. Costello, F.; Coupland, S.; Hodge, W.; Lorello, G.; Koroluk, J.; Pan, Y.; Freedman, M.; Zackon, D.; Kardon, R. Quantifying axonal loss after optic neuritis with optical coherence tomography. Ann. Neurol., 2006, 59(6), 963-969.
31. Beck, R.; Arrington, J.; Murtagh, F.; Cleary, P.A.; Kaufman, D.I.; Experience of the Optic Neuritis Study Group. Brain magnetic resonance imaging in acute optic neuritis. Arch. Neurol., 1993, 50(8), 841-846.
32. Dalton, C.M.; Brex, P.A.; Miszkiel, K.A.; Fernando, K.; MacManus, D.G.; Plant, G.T.; Thompson, A.J.; Miller, D.H. Spinal cord MRI in clinically isolated optic neuritis. J. Neurol. Neurosurg. Psychiatry, 2003, 74(11), 1577-1580.
33. Jacobs, L.; Munschauer, F.; Kaba, S. Clinical and magnetic resonance imaging in optic neuritis. Neurology, 1991, 41(1), 15-19.
34. The Optic Neuritis Study Group. High-and low-risk profiles for the development of multiple sclerosis within 10 years after optic neuritis: experience of the optic neuritis treatment trial. Arch. Ophthalmol., 2003, 121(7), 944-949.
35. The Optic Neuritis Study Group. Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up. Arch. Neurol., 2008, 65(6), 727-732.
36. Lucchinetti, C.; Kiers, L.; O'Duffy, A.; Gomez, M.; Cross, S.; Leavitt, J.; O'Brien, P.; Rodriguez, M. Risk factors for developing multiple sclerosis after childhood optic neuritis. Neurology, 1997, 49(5), 1413-1418.
37. Frisen, L.; Hoyt, W.F. Insidious atrophy of retinal nerve fibers in multiple sclerosis. Funduscopic identification in patients with and without visual complaints. Arch. Ophthalmol., 1974, 92, 91-97.
38. Toussaint, D.; Perier, O.; Verstappen, A.; Bervoets, S. Clinicopathological study of the visual pathways, eyes and cerebral hemispheres in 32 cases of dissemianted sclerosis. J. Clin. Neuroophthalmol., 1983, 3(3), 211-220.
39. Green, A.J.; McQuaid, S.; Hauser, S.L.; Allen, I.V.; Lyness, R. Ocular pathology in multiple sclerosis: retinal atrophy and inflammation irrespective of disease duration. Brain, 2010, 133(Pt 6), 1591-1601.
40. Blumenthal, E.Z.; Parikh, R.S.; Pe'er, J.; Naik, M.; Kaliner, E.; Cohen, M.J.; Prabakaran, S.; Kogan, M.; Thomas, R. Retinal nerve fibre layer imaging compared with histological measurements in a human eye. Eye, 2009, 23(1), 171-175.
41. Parisi, V.; Manni, G.; Spadaro, M.; Colacino, G.; Restuccia, R.; Marchi, S.; Bucci, M.G.; Pierelli, F. Correlation between morphological and functional retinal impairment in multiple sclerosis patients. Invest. Ophthalmol. Vis. Sci., 1999, 40(11), 2520-2527.
42. Trip, S.; A; Schlottmann, P.; Jones, S.; Altmann, D.; Garway-Heath, D.; Thompson, A.; Plant, G.; Miller, D. Retinal nerve fiber layer axonal loss and visual dysfunction in optic neuritis. Ann. Neurol., 2005, 58(3), 383-391.
43. Thurtell, M.J.; Bala, E.; Yaniglos, S.S.; Rucker, J.C.; Peachey, N.S.; Leigh, R.J. Evaluation of optic neuropathy in multiple sclerosis using low-contrast visual evoked potentials. Neurology, 2009, 73(22), 1849-1857.
44. Gordon-Lipkin, E.; Chodkowski, B.; Reich, D.S.; Smith, S.A.; Pulicken, M.; Balcer, L.J.; Frohman, E.; M; Cutter, G.; Calabresi, P.A. Retinal nerve fiber layer is associated with brain atrophy in multiple sclerosis. Neurology, 2007, 69(16), 1603-1609.
45. Syc, S.; B; Saidha, S.; Newsome, S.D.; Ratchford, J.N.; Levy, M.; Ford, E.; Crainiceanu, C.M.; Durbin, M.K.; Oakley, J.D.; Meyer, S.A.; Frohman, E.M.; Calabresi, P.A. Optical coherence tomography segmentation reveals ganglion cell layer pathology after optic neuritis. Brain, 2011, 135(Pt 2), 521-533.
46. Pulicken, M.; Gordon-Lipkin, E.; Balcer, L.J.; Frohman, E.; Cutter, G.; Calabresi, P.A. Optical coherence tomography and disease subtype in multiple sclerosis. Neurology, 2007, 69(22), 2085-2092.
47. Bock, M.; Brandt, A.U.; Kuchenbecker, J.; Dãrr, J.; Pfueller, C.F.; Weinges-Evers, N.; Gaede, G.; Zimmermann, H.; Bellmann-Strobl, J.; Ohlraun, S.; Zipp, F.; Paul, F. Impairment of contrast visual acuity as a functional correlate of retinal nerve fibre layer thinning and total macular volume reduction in multiple sclerosis. Br. J. Ophthamol., 2012, 96(1), 62-67.
48. Galetta, K.; Graves, J.; Talman, L.; Lile, D.; Frohman, E.; Calabresi, P.; Galetta, S.; Balcer, L. Visual pathway loss in benign multiple sclerosis: a longitudional study. Neuroophthalmology, 2012, In Press.
49. Sayao, A.-L.; Devonshire, V.; Tremlett, H. Longitudinal follow-up of benign multiple sclerosis at 20 years. Neurology, 2007, 68(7), 496-500.
50. Strasser-Fuchs, S.; Enzinger, C.; Ropele, S.; Wallner, M.; Fazekas, F. Clinically benign multiple sclerosis despite large T2 lesion load: can we explain this paradox? Mult Scler., 2008, 14(2), 205-211.
51. Ruggeri, M.; Wehbe, H.; Jiao, S.; Gregori, G.; Jockovich, M.E.; Hackam, A.; Duan, Y.; Puliafito, C.A. In vivo three-dimensional high-resolution imaging of rodent retina with spectral-domain optical coherence tomography. Invest. Ophthalmol. Vis. Sci., 2007, 48(4), 1808-1814.
52. Horio, N.; Kachi, S.; Hori, K.; Okamoto, Y.; Yamamoto, E.; Terasaki, H.; Miyake, Y. Progressive change of optical coherence tomography scans in retinal degeneration slow mice. Arch. Ophthalmol., 2001, 119(9), 1329-1332.
53. Li, Q.; Timmers, A.M.; Hunter, K.; Gonzalez-Pola, C.; Lewin, A.S.; Reitze, D.H.; Hauswirth, W.W. Noninvasive imaging by optical coherence tomography to monitor retinal degeneration in the mouse. Invest. Ophthalmol. Vis. Sci., 2001, 42(12), 2981-2989.
54. Hein, K.; Gadjanski, I.; Kretzschmar, B.; Lange, K.; Diem, R.; Sattler, M.; B; Bahr, M. An optical coherence tomography study on degeneration of retinal nerve fiber layer in rats with autoimmune optic neuritis. Invest. Ophthalmol. Vis. Sci., 2012, 53(1), 157-163.
55. Kim, K.; Puoris'haag, M.; Maguluri, G.; Umino, Y.; Cusato, K.; Barlow, R.; Boer, J. Monitoring mouse retinal degeneration with high-resolution spectral-domain optical coherence tomography. J. Vis., 2008, 8(17), 1-11.
56. Gabriele, M.L.; Ishikawa, H.; Schuman, J.S.; Ling, Y.; Bilonick, R.A.; Kim, J.S.; Kagemann, L.; Wollstein, G. Optic nerve crush mice followed longitudinally with spectral domain optical coherence tomography. Invest. Ophthalmol. Vis. Sci., 2011, 52(5), 2250-2254.
57. Quinn, T.A.; Dutt, M.; Shindler, K.S. Optic neuritis and retinal ganglion cell loss in a chronic murine model of multiple sclerosis. Front. Neurol., 2011, 2, 50.
58. Shindler, K.S.; Ventura, E.; Dutt, M.; Rostami, A. Inflammatory demyelination induces axonal injury and retinal ganglion cell apoptosis in experimental optic neuritis. Exp. Eye Res., 2008, 87(3), 208-213.
59. Shindler, K.S.; Guan, Y.; Ventura, E.; Bennett, J.; Rostami, A. Retinal ganglion cell loss induced by acute optic neuritis in a relapsing model of multiple sclerosis. Mult. Scler., 2006, 12(5), 526-532.
60. Shao, H.; Huang, Z.; Sun, S.L.; Kaplan, H.J.; Sun, D. Myelin/Oligodendrocyte Glycoprotein-Specific T-Cells Induce Severe Optic Neuritis in the C57Bl/6 Mouse. Invest. Ophthalmol. Vis. Sci., 2004, 45(11), 4060-4065.
61. Bettelli, E.; Pagany, M.; Weiner, H.L.; Linington, C.; Sobel, R.A.; Kuchroo, V.K. Myelin oligodendrocyte glycoprotein-specific t cell receptor transgenic mice develop spontaneous autoimmune optic neuritis. J. Exp. Med., 2003, 197(9), 1073-1081.
62. Shindler, K.S.; Ventura, E.; Dutt, M.; Elliott, P.; Fitzgerald, D.C.; Rostami, A. Oral resveratrol reduces neuronal damage in a model of multiple sclerosis. J. Neuroophthalmol., 2010, 30(4), 328-339.
63. Barkhof, F.; Calabresi, P.A.; Miller, D.H.; Reingold, S.C. Imaging outcomes for neuroprotection and repair in multiple sclerosis trials. Nat. Rev. Neurol., 2009, 5(5), 256-266.
64. Khatri, B.; Barkhof, F.; Comi, G.; Hartung, H.-P.; Kappos, L.; Montalban, X.; Pelletier, J.; Stites, T.; Wu, S.; Holdbrook, F.; Zhang-Auberson, L.; Francis, G.; Cohen, J.A. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. Lancet Neurol., 2011, 10(6), 520-529.
65. Comi, G.; Cohen, J.A.; Arnold, D.; L; Wynn, D.; Filippi, M. Phase III dose-comparison study of glatiramer acetate for multiple sclerosis. Ann. Neurol., 2011, 69(1), 75-82.
66. Naismith, R.T.; Piccio, L.; Lyons, J.A.; Lauber, J.; Tutlam, N.T.; Parks, B.J.; Trinkaus, K.; Song, S.K.; Cross, A.H. Rituximab addon therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial. Neurology, 2010, 74(23), 1860-1867.
67. Sormani, M.P.; Bonzano, L.; Roccatagliata, L.; Mancardi, G.L.; Uccelli, A.; Bruzzi, P. Surrogate endpoints for EDSS worsening in multiple sclerosis. Neurology, 2010, 75(4), 302-309.
68. Rudick, R.A.; Cutter, G.; Reingold, S. The multiple sclerosis functional composite: a new clinical outcome measure for multiple sclerosis trials. Mult. Scler., 2002, 8(5), 359-365.
69. Miller, D.H.; Grossman, R.I.; Reingold, S.C.; McFarland, H.F. The role of magnetic resonance techniques in understanding and managing multiple sclerosis. Brain, 1998, 121(1), 3-24.
70. Baier, M.L.; Cutter, G.R.; Rudick, R.A.; Miller, D.; Cohen, J.A.; Weinstock-Guttman, B.; Mass, M.; Balcer, L.J. Low-contrast letter acuity testing captures visual dysfunction in patients with multiple sclerosis. Neurology, 2005, 64(6), 992-995.
71. Filippi, M.; Bozzali, M.; Rovaris, M.; Gonen, O.; Kesavadas, C.; Ghezzi, A.; Martinelli, V.; Grossman, R.I.; Scotti, G.; Comi, G.; Falini, A. Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis. Brain, 2003, 126(2), 433-437.
72. Davie, C.A.; Barker, G.J.; Webb, S.; Tofts, P.S.; Thompson, A.J.; Harding, A.E.; McDonald, W.I.; Miller, D.H. Persistent functional deficit in multiple sclerosis and autosomal dominant cerebellar ataxia is associated with axon loss. Brain, 1995, 118(6), 1583-1592.
73. De Stefano, N.; Matthews, P.M.; Fu, L.; Narayanan, S.; Stanley, J.; Francis, G.S.; Antel, J.P.; Arnold, D.L. Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study. Brain, 1998, 121(8), 1469-1477.
74. Henderson, A.P.; Altmann, D.R.; Trip, A.S.; Kallis, C.; Jones, S.J.; Schlottmann, P.G.; Garway-Heath, D.F.; Plant, G.T.; Miller, D.H. A serial study of retinal changes following optic neuritis with sample size estimates for acute neuroprotection trials. Brain, 2010, 133(9), 2592-2602.
75. Frohman, E.M.; Dwyer, M.G.; Frohman, T.; Cox, J.L.; Salter, A.; Greenberg, B.M.; Hussein, S.; Conger, A.; Calabresi, P.; Balcer, L.J.; Zivadinov, R. Relationship of optic nerve and brain conventional and non-conventional MRI measures and retinal nerve fiber layer thickness, as assessed by OCT and GDx: A pilot study. J. Neurol. Sci., 2009, 282(1-2), 96-105.
76. Daumer, M.; Neuhaus, O.; Morrissey, S.; Hintzen, R.Q.; Ebers, G. MRI as an outcome in multiple sclerosis clinical trials. Neurology, 2008, 72(8), 705-711.
77. Kapoor, R.; Furby, J.; Hayton, T.; Smith, K.J.; Altmann, D.R.; Brenner, R.; Chataway, J.; Hughes, R.A.; Miller, D.H. Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Neurol., 2010, 9(7), 681-688.
78. Hayton, T.; Furby, J.; Smith, K.; Altmann, D.; Brenner, R.; Chataway, J.; Hunter, K.; Tozer, D.; Miller, D.; Kapoor, R. Longitudinal changes in magnetisation transfer ratio in secondary progressive multiple sclerosis: data from a randomised placebo controlled trial of lamotrigine. J. Neurol., 2011, 1-10.
79. Giacomini, P.S.; Arnold, D.L. Non-conventional MRI techniques for measuring neuroprotection, repair and plasticity in multiple sclerosis. Curr. Opin. Neurol., 2008, 21(3), 272-277.
80. Filippi, M.; Rocca, M.A. MR imaging of multiple sclerosis. Radiology, 2011, 259(3), 659-681.
81. Smith, S.A.; Williams, Z.R.; Ratchford, J.N.; Newsome, S.D.; Farrell, S.K.; Farrell, J.A.; Gifford, A.; Miller, N.R.; van Zijl, P.C.; Calabresi, P.A.; Reich, D.S. Diffusion tensor imaging of the optic nerve in multiple sclerosis: association with retinal damage and visual disability. AJNR Am. J. Neuroradiol., 2011, 32(9), 1662-1668.
82. Greenberg, B.M. Optical coherence tomography as a potential readout in clinical trials. Ther. Adv. Neurol. Dis., 2010, 3(3), 153-160.
83. Fisher, J.B.; Jacobs, D.A.; Markowitz, C.E.; Galetta, S.L.; Volpe, N.J.; Nano-Schiavi, M.; Ligia; Baier, M.L.; Frohman, E.M.; Winslow, H.; Frohman, T.C.; Calabresi, P.A.; Maguire, M.G.; Cutter, G.R.; Balcer, L.J. Relation of visual function to retinal nerve fiber layer thickness in multiple sclerosis. Ophthalmol., 2006, 113(2), 324-332.
84. Talman, L.S.; Bisker, E.R.; Sackel, D.J.; Long, D.A.; Galetta, K.M.; Ratchford, J.N.; Lile, D.J.; Farrell, S.K.; Loguidice, M.J.; Remington, G.; Conger, A.; Frohman, T.C.; Jacobs, D.A.; Markowitz, C.E.; Cutter, G.R.; Ying, G.S.; Dai, Y.; Maguire, M.G.; Galetta, S.L.; Frohman, E.M.; Calabresi, P.A.; Balcer, L.J. Longitudinal study of vision and retinal nerve fiber layer thickness in multiple sclerosis. Ann. Neurol., 2010, 67(6), 749-760.
85. Albrecht, P.; Fröhlich, R.; Hartung, H.P.; Kieseier, B.; Methner, A. Optical coherence tomography measures axonal loss in multiple sclerosis independently of optic neuritis. J. Neurol., 2007, 254(11), 1595-1596.
86. Siger, M.; Dziegielewski, K.; Jasek, L.; Bieniek, M.; Nicpan, A.; Nawrocki, J.; Selmaj, K. Optical coherence tomography in multiple sclerosis: thickness of the retinal nerve fiber layer as a potential measure of axonal loss and brain atrophy. J. Neurol., 2008, 255(10), 1555-1560.
87. Grazioli, E.; Zivadinov, R.; Weinstock-Guttman, B.; Lincoff, N.; Baier, M.; Wong, J.R.; Hussein, S.; Cox, J.L.; Hojnacki, D.; Ramanathan, M. Retinal nerve fiber layer thickness is associated with brain MRI outcomes in multiple sclerosis. J. Neurol. Sci., 2008, 268(1-2), 12-17.
88. Pueyo, V.; Martin, J.; Fernandez, J.; Almarcegui, C.; Ara, J.; Egea, C.; Pablo, L.; Honrubia, F. Axonal loss in the retinal nerve fiber layer in patients with multiple sclerosis. Mult. Scler., 2008, 14(5), 609-614.
89. Keltner, J.L.; Cello, K.E.; Balcer, L.J.; Calabresi, P.A.; Markowitz, C.E.; Werner, J.S. Stratus OCT quality control in two multi-centre multiple sclerosis clinical trials. Neuroophthalmol., 2011, 35(2), 57-64.
90. Garcia-Martin, E.; Pueyo, V.; Pinilla, I.; Ara, J.-R.; Martin, J.; Fernandez, J. Fourier-domain OCT in multiple sclerosis patients: reproducibility and ability to detect retinal nerve fiber layer atrophy. Invest. Ophthalmol. Vis. Sci., 2011, 52(7), 4124-4131.
91. Huggins, A.; Sergott, R.C. Background and rationale for mechanism of action, efficacy, and safety of fingolimod (Gilenya), the first oral therapy for remitting-relapsing multiple sclerosis: with special emphasis upon visual safety. Curr. Opin. Ophthalmol., 2011, 22(6), 447-450.
92. Cettomai, D.; Pulicken, M.; Gordon-Lipkin, E.; Salter, A.; Frohman, T.C.; Conger, A.; Zhang, X.; Cutter, G.; Balcer, L.J.; Frohman, E.M.; Calabresi, P.A. Reproducibility of optical coherence tomography in multiple sclerosis. Arch. Neurol., 2008, 65(9), 1218-1222.
93. Sergott, R.C.; Frohman, E.; Glanzman, R.; Al-Sabbagh, A. The role of optical coherence tomography in multiple sclerosis: Expert panel consensus. J. Neurol. Sci., 2007, 263(1-2), 3-14.
94. Kanamori, A.; Escano, M.F.; Eno, A.; Nakamura, M.; Maeda, H.; Seya, R.; Ishibashi, K.; Negi, A. Evaluation of the effect of aging on retinal nerve fiber layer thickness measured by optical coherence tomography. Ophthalmol. J. Int. d'ophtalmol. Int. J. Ophthalmol., 2003, 217(4), 273-278.
95. Syc, S.B.; Warner, C.V.; Hiremath, G.S.; Farrell, S.K.; Ratchford, J.N.; Conger, A.; Frohman, T.; Cutter, G.; Balcer, L.J.; Frohman, E.M.; Calabresi, P.A. Reproducibility of high-resolution optical coherence tomography in multiple sclerosis. Mult. Scler., 2010, 16(7), 829-839.
96. Davies, E.C.; Galetta, K.M.; Sackel, D.J.; Talman, L.S.; Frohman, E.M.; Calabresi, P.A.; Galetta, S.L.; Balcer, L.J. Retinal ganglion cell layer volumetric assessment by spectral-domain optical coherence tomography in multiple sclerosis: application of a high precision manual estimation technique. J. Neuroophthalmol., 2011, 31(3), 260-264.
97. Tan, O.; Chopra, V.; Lu, A.T.; Schuman, J.S.; Ishikawa, H.; Wollstein, G.; Varma, R.; Huang, D. Detection of macular ganglion cell loss in glaucoma by Fourier-domain optical coherence tomography. Ophthalmology, 2009, 116(12), 2305-2314.
98. Serbecic, N.; Aboul-Enein, F.; Beutelspacher, S.C.; Vass, C.; Kristoferitsch, W.; Lassmann, H.; Reitner, A.; Schmidt-Erfurth, U. high resolution spectral domain optical coherence tomography (sdoct) in multiple sclerosis: the first follow up study over two years. PLoS ONE, 2011, 6(5), e19843.